Reports Q3 revenue $116.46M, consensus $91.71M."This quarter we made significant progress on our transformation journey. We began to establish the foundations of our future strategy and position the Company for resetting our financial base which is designed to achieve our long-term financial success. We believe we hold a unique position in healthcare as we power the industry with effortless point-of-care diagnostic testing, sample collection, multi-ome services, and innovation. By doing this, we connect healthcare to people and help increase access, affordability, and quality of care," said OraSure president and CEO Carrie Eglinton Manner.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OSUR:
- OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)
- OraSure’s COVID-19 Rapid Test available in Amazon’s online store
- InteliSwab® COVID-19 Rapid Test Now Available in Amazon’s Online Store
- 2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET
- OraSure receives $8.6M BARDA contract to develop 2nd generation Ebola test